19-24-03

PTO/SB/21 (08-03) Approved for use through 08/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ed to respond to a collection of information unless it displays a valid OMB control number e Paperwork Reduction Act of 1995, no pe Application Number 10/643,824 TRANSMITTAL Filing Date FORM First Named Inventor Nelson Ernest Peter Art Unit (to be used for all correspondence after initial filing) Examiner Name Attorney Docket Number Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance communication Fee Transmittal Form Drawing(s) to Technology Center (TC) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Identify below): Extension of Time Request Request for Refund Express Abandonment Request Information Disclosure Statement CD, Number of CD(s) Remarks Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Kenneth A. Keeling Keeling Hudson, L.L.C. Individual name Signature Date CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. ER 216 164 121 US Typed or printed name Kenneth A. Keeling Date Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to Inscinence or information is required by 37 CH+1.3. In enformation is required do other or train a benefit by the public which is to the feel of by the USP<sup>21</sup> received by 30 CH+1.3. In enformation is required by 30 CH+1.3. The checkens are sentimented for Emission Checkens and the Checkens are sent to the Checkens and the Checkens are sent to ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ernest Peter Nelson

Serial No.: 10/643,824

Group No.:

Filed: Examiner:

For: LEG USCER, LYMPHOEDEMA AND DVT VIBRATORY TREATMENT DEVICE

Commissioner for Patents Washington DC 20231

#### INFORMATION DISCLOSURE STATEMENT

# List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

- Preliminary Statements
- Forms PTO 1449 (now PTO/SB/08A and 08B)
- 3. Copies of Listed Information Items Accompanying This Statement
- 4. Concise Explanation of English Language Listed Information Items
- 5. Identification of Person(s) Making This Information Disclosure Statement

### Section 1. Preliminary Statements

Applicant(s) submits herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information

#### CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as attached thereto are being deposited with the United States Postal Service on the date listed below, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number ER 216 164 121 US, addressed to the: Commissioner for Patents, Washington, DC 20231.

9-23-03

Kenneth A. Keeling Registration No. 31,842 cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

#### Section 2. PTO 1449 (Now Forms PTO/SB/08A and 08B)

PTO Form 1449 is attached hereto.

## Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

## Section 4. Concise Explanation of English Language Listed Information Items

- 1. "The Use of Cycloidal Vibrations Therapy on Blood and Lymph Circulation and on Wound Healing," presented at the VII International Congress of Lymphology, Firenze, Italy on October 28 to November 2, 1979 by Lievens, Leduc and Dewald
- Suggests that some aspects of wound healing in test mice were improved by a regime of cycloidal vibrations.
- 2. "The Effect of cycloid Vibration on Leg Blood Flow and Ulcer Pain." presented to the Section of Dermatology of the Royal Society of Medicine in 1978 by Pickup, Alexander, and Gosling Discloses that while vibration was recognized to dramatically reduce pain from leg ulcers, only a slight improvement in healing was noticed.
- 3. "The Effects of Vibration Upon Blood-Viscosity and Red-Cell Mobility: A Study In Vivo and In-Vitro," by Ramcharan, Shoja, Piggott and Taylor, published in Biorheology Vol. 19, pages 341 to 352 in 1982
- Presents studies of three dimensional, or "cycloid" vibration showing that vibration of either human or rabbit blood in vitro has no effect on blood-viscosity at any sheer rate, on red cell mobility, on zeta-potential or on yield stress. Whole-body vibration produced no significant effect on rheology at rates of shear above 2 s-l, but low-shear viscosity (<1 s-l Shear rate) became more Newtonian after vibration, with a significant reduction in yield stress from 5.71 +/-0.14 mNm-2 to 3.54 +/-0.32 mNm-2.
- 4. "The Effects of Vibration on Skin Blood Flow." by Ryan and Salter, published in Biblotheca Anatomica, No. 16, pages 180 – 184 in 1977 and presented at the 9<sup>th</sup> European Conference of Microcirculation in Antwerp, Belgium in 1976

Presents interpretation on effect of vibration. Concludes that the effect of vibration is primarily to disperse tissue fluid, which is therapeutically useful for conditions where stiffness, pain or swelling are directly related to an excess of fluid in the tissues.

5. "Improvement of Blood Flow in Ischaemic Limbs by the Use of Cycloid Vibration Therapy by Askari and Rozov (No publication date is available)
Presents a trial study of applying cycloid vibration to patients with cases of severe occlusive peripheral vascular disease.

# Section 5. Identification of Person(s) Making This Information Disclosure Statement

The person making this statement is:									
	(a)	☐ the invent	or(s) who signs below.						
	(b)	an individ	lual associated with the filing and prosecution of this application.						
	(c)	■ the practi	tioner who signs below on the basis of the information:						
			supplied by the inventor(s). supplied by an individual associated with the filing and prosecution of this application (37 CFR 1.56(c)) in the practitioner's file.						

Respectfully submitted,

Kenneth A. Keeling Registration No. 31,842 James E. Hudson III Registration No. 41,081

September 2**3**, 2003 Keeling Hudson L.L.C. 901 North Post Oak Road Houston, Texas 77024 713-680-1447 713-680-8567 (Fax)

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>.</b>				C IIIpi L II III.			
AUENT	for form 1449/PTO			Applicati n Number Filing Date First Named Inventor	10/643,824		
INF	ORMATION	DIS	CLOSURE				
STA	TEMENT E	BY A	PPLICANT		Ernest Peter Nelson		
				Art Unit			
(Use as many sheets as necessary)				Examiner Name			
Sheet	1	of	1	Attorney Docket Number			

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serlal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LIEVENS, LEDUC, DEWALD, "The Use of Cycloidal Vibrations Therapy on Blood and Lymph Circulation and	
		on Wound Healing," VII International Congress of Lymphology, 10/28/1979 to 11/2/1979, Firenze, Italy	
	-	FICKUP, ALEXANDER, GOSLING, "The Effect of cycloid Vibration on Leg Blood Flow and Ulcer Pain,"	
		Section of Dermatology of the Royal Society of Medicine, 1978.	
		RAMCHARAN, SHOJA, PIGGOTT, TAYLOR, "The Effects of Vibration Upon Blood- Viscosity and Red-Cell	
		Mobility: A Study In Vivo and In-Vitro," Biorheology, 1982, Vol 19, Pergamon Press Ltd., USA.	
	-	RYAN, SALTER, "The Effects of Vibration on Skin and Blood Flow," Biblotheca Anatomica, 1977, Vol. 16	
		S. Karger, Basel, Switzerland	
		ASKARI, ROZOV, "Improvement of Blood Flow in Ischaemic Limbs by the Use of Cycloid Therapy," Israel. (no date).	
		Other publication information not available.	

Date Examiner /Steven Douglas/ 07/22/2009 Considered Signature

red, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

consistent Include copy of this form with next communication to applicant. In Applicant's unique unable designation university entire 2, Applicant's to be been achieve mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.86. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 30 CFR 1.86. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO. Time will vary depending upon the individual case. Any comments on the application of the information and public the information application of the information and information of the in

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.